CRBU — Caribou Biosciences Share News
0.000.00%
Last trade - 00:00- $57.12m
- -$55.19m
- $11.16m
Caribou Biosciences Q3 net loss narrows
Brief: Caribou Biosciences Q3 Licensing And Collaboration Revenue USD 2.198 Million
Advisory: Alert inadvertently tagged to Caribou Biosciences withdrawn
Brief: Caribou Biosciences Expects Cash And Marketable Securities As Of Sept 30 To Be $159.2 Million
Brief: Caribou Biosciences Q2 Licensing And Collaboration Revenue USD 2.667 Million
Brief: EV Owners Save Most on Auto Loan Refinancing, Caribou Finds—Time to Stack EV & OBBBA Benefits Before Tax Credits End
Caribou Biosciences Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Caribou Biosciences Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Caribou Biosciences Q1 Basic EPS USD -0.43
Caribou Biosciences rises on job cuts, shifts focus to cancer therapies
Brief: Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lennar, Redfin
Brief: Caribou Biosciences Announces The FDA Has Granted Fast Track Designations To CB-010 In Refractory SLE And To CB-012 In Relapsed Or Refractory AML
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
Analysis: Rotation trade takes small caps from dead money to Wall Street darlings
Brief: Caribou Biosciences Discontinued Preclinical Research Activities Associated With Allogeneic Car-Nk Platform, Reduced Workforce By 21 Positions
Nasdaq biotech index hits over 2-1/2 yr high
Brief: Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
U.S. RESEARCH ROUNDUP-Honeywell International, Stericycle, Target Corp